Navidea Biopharmaceuticals Posts Lymphoseek® NDA Update to Company Website

Before you go, we thought you'd like these...
Before you go close icon

Navidea Biopharmaceuticals Posts Lymphoseek®NDA Update to Company Website

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents, today posted on its website an update to the status of the Lymphoseek NDA review. The web access to the statement can be found on the Navidea Investor page at: http://phx.corporate-ir.net/phoenix.zhtml?c=68527&p=irol-nda




Navidea Biopharmaceuticals
Brent Larson, 614-822-2330
Sr. VP & CFO

KEYWORDS:   United States  North America  Ohio

INDUSTRY KEYWORDS:

The article Navidea Biopharmaceuticals Posts Lymphoseek® NDA Update to Company Website originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners